Ke, Shizhong
Dang, Fabin http://orcid.org/0000-0002-1954-8231
Wang, Lin http://orcid.org/0000-0002-2061-4224
Chen, Jia-Yun
Naik, Mandar T.
Li, Wenxue http://orcid.org/0000-0002-8902-0184
Thavamani, Abhishek
Kim, Nami
Naik, Nandita M.
Sui, Huaxiu
Tang, Wei
Qiu, Chenxi
Koikawa, Kazuhiro
Batalini, Felipe http://orcid.org/0000-0003-3354-308X
Stern Gatof, Emily
Isaza, Daniela Arango
Patel, Jaymin M. http://orcid.org/0000-0001-9945-5555
Wang, Xiaodong
Clohessy, John G. http://orcid.org/0000-0001-5186-9775
Heng, Yujing J. http://orcid.org/0000-0002-8930-817X
Lahav, Galit
Liu, Yansheng http://orcid.org/0000-0002-2626-3912
Gray, Nathanael S. http://orcid.org/0000-0001-5354-7403
Zhou, Xiao Zhen
Wei, Wenyi
Wulf, Gerburg M. http://orcid.org/0000-0001-7868-6231
Lu, Kun Ping http://orcid.org/0000-0002-0734-1567
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health (P50CA168504, R01CA226776, R35CA253027, K99CA263194, R01CA205153, R01AG055559)
U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health
U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health
U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health
U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health
U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health
Article History
Received: 1 May 2023
Accepted: 2 April 2024
First Online: 15 April 2024
Competing interests
: S.K., G.M.W., N.S.G., X.Z.Z., and K.P.L. are inventors of several issued patents and/or pending patent applications on PIN1, PIN1 biomarkers, PIN1 inhibitors and PIN1 inhibitor combination to treat human diseases; X.Z.Z. and K.P.L. are the scientific founders and former scientific advisors of and own equity in Pinteon. Their interests were reviewed and managed by BIDMC in accordance with its conflict-of-interest policy. G.M.W. reports research funding from Glaxo Smith Kline (institutional funding). W.W. is a co-founder and consultant for the Rekindle Therapeutics. N.S.G. is a founder, science advisory board member (SAB) and equity holder in Syros, C4, Allorion, Lighthorse, Inception, Voronoi, Matchpoint, Shenandoah (board member), Larkspur (board member) and Soltego (board member). The Gray lab receives or has received research funding from Novartis, Takeda, Astellas, Taiho, Jansen, Kinogen, Arbella, Deerfield and Sanofi. All other authors do not have any competing interests.